Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: $6T

Relative Value

There is not enough data to reliably calculate the relative value of PNEXF.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PNEXF Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

PNEXF Competitors Multiples
Pharnext SCA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
387B USD 6.5 164.8 16 22.7
US
Amgen Inc
NASDAQ:AMGN
184.5B USD 5.1 26.4 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD 6 21.5 14.6 14.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD 10.4 33.1 24.4 25.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
86.9B AUD 3.8 19.8 9.1 11.3
NL
argenx SE
XBRU:ARGX
44B EUR 14.1 33.2 67.2 69.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -78.2 -70.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.1B USD 14.4 1 059.6 142.7 173.1
P/S Multiple
Revenue Growth P/S to Growth
FR
Pharnext SCA
OTC:PNEXF
Average P/S: 3 068 054.2
33 746 422.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
6
4%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.4
10%
1
US
E
Epizyme Inc
F:EPE
2 087.6
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.4
47%
0.3
P/E Multiple
Earnings Growth PEG
FR
Pharnext SCA
OTC:PNEXF
Average P/E: 172
Negative Multiple: -160 391.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
164.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
21.5
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
33.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
33.2
42%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 059.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
FR
Pharnext SCA
OTC:PNEXF
Average EV/EBITDA: 38.7
Negative Multiple: -165 649.1
N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.9
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
7%
2.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
9.1
8%
1.1
NL
argenx SE
XBRU:ARGX
67.2
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -78.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
142.7
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
FR
Pharnext SCA
OTC:PNEXF
Average EV/EBIT: 44.2
Negative Multiple: -163 758.9
N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
11.3
11%
1
NL
argenx SE
XBRU:ARGX
69.1
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -70.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
173.1
N/A N/A